Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|October 13, 2021
Daily OTC Pearl: Vitamin B-6
Author(s)Saro Arakelians, PharmD
People with kidney disease or conditions that prevent the small intestine from absorbing nutrients from foods are more likely to be vitamin B-6 deficient.
Advertisement
OTC/Lifestyle Pearl of the Day: Vitamin B-6
Indication: Vitamin B-6 (pyridoxine) is important for normal brain development and for keeping the nervous system and immune system healthy.
Insight:
- Food sources of vitamin B-6 include poultry, fish, potatoes, chickpeas, bananas, and fortified cereals.
- Vitamin B-6 can also be taken as a supplement, typically as an oral capsule, tablet, or liquid.
- People with kidney disease or conditions that prevent the small intestine from absorbing nutrients from foods (malabsorption syndromes) are more likely to be vitamin B-6 deficient.
- A vitamin B-6 deficiency is usually coupled with deficiency in other B vitamins, such as folic acid (vitamin B-9) and vitamin B-12.
- Interactions may include with altretamine, barbiturates, anticonvulsants, and levodopa.
- Recommended daily allowance: The recommended daily amount of vitamin B-6 for adults 50 years of age and younger is 1.3 milligrams. After age 50, the recommended daily amount is 1.5 milligrams for women and 1.7 milligrams for men.
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
3
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
4
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
5